ZCM
BBIO icon

Ziegler Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Ziegler Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-27,994
Closed -$1.13M – 404
2023
Q4 		$1.13M Sell
27,994
-473
-2% -$14.2K 0.05% 264
2023
Q3 		$751K Sell
28,467
-178
-0.6% -$5.05K 0.03% 297
2023
Q2 		$493K Buy
+28,645
New +$431K 0.02% 350

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ziegler Capital Management's BBIO Position: Q1 2024 in Review

Ziegler Capital Management sold out of BridgeBio Pharma (BBIO) in Q1 2024, closing a stake of 27,994 shares — an estimated $1.13M sold.

Ziegler Capital Management first reported a position in BBIO in Q2 2023 and held it in 3 quarters. The position peaked at $1.13M in Q4 2023. 244 funds tracked by Wall St. Rank hold BBIO as of Q1 2024.

  • Ziegler Capital Management reported no remaining BridgeBio Pharma position as of Q1 2024 after selling out during the quarter.
  • Ziegler Capital Management sold 27,994 BridgeBio Pharma shares in Q1 2024, an estimated $1.13M.
  • Ziegler Capital Management first reported a position in BridgeBio Pharma in Q2 2023 and held it in 3 quarters.
  • Ziegler Capital Management's BridgeBio Pharma position peaked at $1.13M in Q4 2023.
  • 244 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2024.

Based on Ziegler Capital Management's 13F filing for Q1 2024, filed 15 May 2024.